Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples